

60

---

(12) UK Patent Application (19) GB (11) 2 109 231 A

---

- (21) Application No 8229804  
(22) Date of filing 19 Oct 1982  
(30) Priority data  
(31) 8120034  
(32) 26 Oct 1981  
(33) France (FR)  
(43) Application published  
2 Jun 1983  
(51) INT CL<sup>3</sup>  
A61K 9/06 31/56  
(52) Domestic classification  
A6B 826 L  
(56) Documents cited  
GB 1593953  
GB 1047519  
GB 1047518  
EP A 0020794  
(58) Field of search  
A6B  
(71) Applicants  
Jean Louis Abel Besine,  
23 rue Reynoard,  
75016 Paris,  
France.  
(72) Inventors  
Jean Louis Abel Besine  
(74) Agent and/or Address for  
Service  
Marks and Clerk,  
Scottish Life House,  
Bridge Street,  
Manchester M3 3DP.

(54) Medicament containing  
progesterone

(57) A medicament, for the treatment  
of mammary disorders such as mas-  
todynia and mastopathias, is in the  
form of a gel containing progesterone  
and is administered percutaneously.

GB 2 109 231 A

## SPECIFICATION

## Medicament based on progesterone

- 5 The present invention relates to a medicament based on progesterone for the treatment of mammary disorders such as mastodynias and mastopathias.

- 10 This medicament is characterized in that the progesterone is in the form of gel applied by the percutaneous route.

- In fact, it has been discovered, according to the invention, that progesterone, among the hormonal steroids, presents the particular feature of being  
15 metabolized in the skin into derivatives whose hormonal activity appears to be virtually zero. This results in that, when a solution of progesterone is administered by the percutaneous route, 80% of the steroids are metabolized in the skin and only 20%  
20 are capable of passing the cutaneous barrier. The percutaneous administration of progesterone therefore offers a particular advantage in mammary pathology, since it allows administration and concentration within the mammary receptor itself of a large quantity of progesterone. On the other hand, a concentration just sufficient for a therapeutic effect at mammary level is often obtained, by the oral or injectable route, only at the cost of excessive activity at uterine level, sometimes causing an atrophy of the  
30 tunica mucosa uteri, or even a metrorrhagia. The percutaneous route therefore enables the disparity of the respective concentrations to be reversed and the desired effect on the mammary gland to be obtained, without undesirable repercussions on the  
35 uterus.

- According to the invention, the progesterone is therefore applied by the percutaneous route in the form of a dilute alcoholic gel having a concentration of 1%. In other words, for 100 grams of composition,  
40 the progesterone is present at the rate of 1 gram and the excipient is constituted by a carboxypolyvinyl polymer, triethanolamine, 95% alcohol and purified water. The progesterone, at breast level, opposed the increase in the capillary permeability provoked by the oestrogens, it participates in the growth and  
45 differentiation of the galactophori and acini and it blocks the cycle of the rapid epithelial mitoses provoked by the oestrogens.

- The administration of pure progesterone by the  
50 percutaneous route makes it possible to treat and prevent the vascular and cellular effects of a local deficit of progesterone at breast level. It may be employed in all cases of benign mammary pathology, such as mastodynias, mastopathias, prevention  
55 of recurrences (cysts, adeno-fibromas). Therapeutic tests have been made on a group of 52 women, in two ways namely:

- In a first group, only the progesterone was administered by the percutaneous route in 26 patients  
60 whilst, in the second group of 26 patients, the progesterone was administered by the percutaneous route in association with a synthetic luteomimetic, an oestropogestative or other hormonal medication.

- 65 In each of the two groups of 26 patients, the

following had been observed: essential mastodynias, i.e. painful phenomena of congestion without any morphological substratum on physical examination (four times in group 1, six times in group 2); a

- 70 mastopathia in the form of an isolated cystic dystrophy or of multiple microcysts without mastodynias (five times in group 1, four times in group 2); a mammary dystrophy associated with a mastodynia (thirteen times in group 1, eight times in group 2);  
75 the existence of organised benign mammary formations associated or not with a mastodynia and/or with a cystic dystrophy (four times in group 1, eight times in group 2).

- In the 52 patients referred to above, the progesterone was administered by the percutaneous route in the form of dilute alcoholic gel at a concentration of 1%. A dose of 5 grams was applied to the two  
80 breasts each day, from the beginning of the cycle and during menstruation for one month, then in the second part of the cycle during the following two months.

- In group 1, the results were excellent in eight cases and good in seven cases. The results were considered as being excellent when an improvement or disappearance of the mastodynia, a regression of the mammary swelling with disappearance of the local phenomena of cutaneous hypervascularisation and, when associated with a mastopathia, an involution of the latter, were observed in the patients.  
90 The results were considered good when the mastodynia disappeared and the mastoic element persisted, and mediocre when there was persistence of the disorders, although they were attenuated. In group 1, only seven mediocre cases and three failures were  
100 obtained.

- With the patients of group 2, the results varied depending on the therapeutic association of the percutaneous progesterone and, the luteomimetics of synthetic oestropogestatives by the oral route. In  
105 virtually all types of association, a majority of cases with excellent or good results was always encountered. General tolerance was excellent in all cases. No repercussions of the percutaneous therapy by progesterone was observed on the menstrual cycle, nor on the digestive, particularly hepatic, function,  
110 nor did the patients put on weight, as may be the case when luteomimetics or oestropogestatives are taken orally. No local cutaneous intolerance was observed during application, nor allergic phenomenon nor cutaneous pigmentation.

## CLAIMS

1. Medicament based on progesterone for the  
120 treatment of mammary disorders such as mastodynias and mastopathias, wherein it is presented in the form of gel for application by the percutaneous route.  
2. The medicament of claim 1, wherein it is constituted by a dilute alcoholic gel.  
3. The medicament of claim 2, wherein it comprises 1% of pure progesterone.  
4. The medicament of claim 3, wherein the excipient is constituted by a carboxypolyvinyl polymer, triethanolamine, 95% alcohol and purified  
130

water.

5. Medicament substantially as hereinbefore described.

---

Printed for Her Majesty's Stationery Office, by Croydon Printing Company Limited, Croydon, Surrey, 1983.  
Published by The Patent Office, 28 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.